Skip to content

LivaNova LIVN Additional Paid-In Capital

Additional Paid-In Capital at other companies

Haemonetics logo
HaemoneticsHAE
$554.14M+5.9%
ITG
Integer HoldingsITGR
$755.87M+0.2%
Boston Scientific logo
Boston ScientificBSX
$21.58B+2.2%
Stryker logo
StrykerSYK
$2.65B+8.5%
Novanta logo
NovantaNOVT
$556.41M+609%
ResMed logo
ResMedRMD

Other financials

Income statement

See full
Revenue$362.3M+14.3%
Gross profit$243.7M+12.7%
Operating income$41.5M-14.7%
Net income$22.3M+107%
EPS (diluted)$0.40+107%

Balance sheet

See full
Cash & equivalents$539.7M-26.9%
Total debt$340.9M-49.7%
Total equity$1.2B+17.1%
Total assets$2.5B-1.7%

Cash flow

See full
Operating cash flow$15.2M-36.5%
CapEx$14.3M+32.4%
Free cash flow$926.0K-93.0%

Valuation

See full
Market cap$4.32B+62.8%

Profitability

See full
Gross margin67.5%-0.5pp
Operating margin13.4%+0.8pp
Net margin-16.1%-18.0pp
FCF margin11.2%-0.2pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.4×
Current ratio1.3×-0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: LivaNova’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LivaNova's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LivaNova's additional paid-in capital?
LivaNova (LIVN) reported additional paid-in capital of $2.25B in Q1 2026.
How has LivaNova's additional paid-in capital changed year-over-year?
LivaNova's additional paid-in capital increased by 1.4% year-over-year, from $2.22B to $2.25B.
What is the long-term trend for LivaNova's additional paid-in capital?
Over 5 years (2020 to 2025), LivaNova's additional paid-in capital has grown at a 5.0% compound annual growth rate (CAGR), from $1.77B to $2.25B.
What does additional paid-in capital mean?
This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.